Abstract
Glioblastoma multiforme (GBM) accounts for 15-20% of neurological tumors and being considered the most aggressive. Biological heterogeneity and resistance to chemotherapy are the major obstacles facing the development of effective treatment for GBM. Several genes and signaling pathways have been identified to be responsible for the aggressive phenotype of this tumor. The NF-ºB pathway is …